Astellas Pharma Inc. v. Zydus Pharmaceuticals (USA) Inc.
1:24-cv-00940
Overview
Parties
Defendant
Zydus Lifesciences Limited NPE (University / Research)
Represented By
7 Attorneys ListedYoung Conaway Stargatt & Taylor
Young Conaway Stargatt & Taylor, 1000 North King Street
Zydus Pharmaceuticals (USA) Inc. Operating Company
Represented By
7 Attorneys ListedYoung Conaway Stargatt & Taylor
Young Conaway Stargatt & Taylor, 1000 North King Street
Plaintiff
Astellas Pharma Global Development, Inc. Operating Company
Represented By
5 Attorneys ListedMcCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
McCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
Astellas Ireland Co., Ltd. Operating Company
Represented By
5 Attorneys ListedMcCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
McCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
Astellas Pharma Inc. Operating Company
Represented By
5 Attorneys ListedMcCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
McCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360° Radar 6 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| 🇺🇸 United States | Asserted | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → |
Patents Involved
There is a single patent involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US12059409
Pharmaceutical composition for modified release
|
Filed: 2024-03-22
Issued: 2024-08-13
|
Active (17.3 yrs remaining)
Expires: 2044-03-22
|
Patent Enforceability & Injunction Risk Assessment
Active Threat — Patent is within enforceable statutory term; injunctive relief viable.
Standard Statutory Term — No obviousness-type double patenting noted.
Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. Standard Maintenance Fee Schedule Tracked.